Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diffuse Systemic Sclerosis Clear all
Not yet recruiting Phase 1 Interventional

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

NCT07854483
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02228850
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 21, 2026, 1:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

NCT03831438
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
AVID200
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 21, 2026, 1:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Screening Strategies for Scleroderma PAH

NCT01959815
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Scleroderma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 21, 2026, 1:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 21, 2026, 1:39 PM EDT
Withdrawn Phase 2 Interventional

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

NCT01047072
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
fludarabine phosphate, total-body irradiation, tacrolimus, mycophenolate mofetil, rituximab, cyclophosphamide, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Radiation · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111
View directory record Official record
Conditions
Scleroderma, Raynaud's Syndrome
Interventions
Onabotulinumtoxin A, sterile saline solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 21, 2026, 1:39 PM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Scleroderma
Interventions
Tibulizumab, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 1 Interventional

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 21, 2026, 1:39 PM EDT
Not listed Phase 3 Interventional

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

NCT00934427
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 1Phase 2 Interventional

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428
View directory record Official record
Conditions
Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions
UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 21, 2026, 1:39 PM EDT
Terminated Phase 1Phase 2 Interventional

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
KYV-101, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048776
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 21, 2026, 1:39 PM EDT
Completed No phase listed Observational

Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study

NCT00341198
View directory record Official record
Conditions
Autoimmune Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:39 PM EDT
Active, not recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 21, 2026, 1:39 PM EDT
Terminated Not applicable Interventional

UVA1 Light for Scleroderma and Similar Conditions

NCT00476697
View directory record Official record
Conditions
Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
Interventions
German manufactured UVA1 emitting light system
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Not applicable Interventional Results available

TENS in Scleroderma

NCT06646913
View directory record Official record
Conditions
Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

NCT00378521
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 21, 2026, 1:39 PM EDT
Terminated Phase 1 Interventional

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

NCT00040651
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 21, 2026, 1:39 PM EDT